Antithymocyte Globulin | Aplastic Anemia and MDS International Foundation

Antithymocyte Globulin

ATG is an immunosuppressant, a drug that lowers the body's immune response. It is typically used with cyclosporine as the first-line immunosuppressive therapy (IS) to treat patients with acquired aplastic anemia. In some cases it is used as a treatment for patients with MDS and PNH.
Brand name: 
ATG, Atgam, Thymoglobulin
Bone Marrow Disease(s): 
aplastic anemia
myelodysplastic syndromes (MDS)
paroxysmal nocturnal hemoglobinuria (PNH)

Scientists believe that aplastic anemia happens when the immune system attacks and destroys bone marrow stem cells. ATG kills the specific cells that are attacking the bone marrow stem cells. This allows the bone marrow to grow and make new blood cells. ATG may be used to treat other bone marrow failure diseases in some cases. ATG is approved by the U.S. Food and Drug Administration (FDA) for treating moderate and severe aplastic anemia. ATG is commonly used with another drug called cyclosporine.

Related Clinical Trials

Clinical Trialsort descending Status Age Group
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy Recruiting up to 75 years
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor Recruiting up to 19 years old
Busulfan and Cyclophosphamide Followed By ALLO BMT Recruiting up to 44 year
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies Recruiting 1 to 80 years
Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia Recruiting Up to 59 years
Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia Recruiting 2 years and older
Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia Recruiting up to 60 years
Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia Recruiting Up to 70 years
Horse ATG in Patients With AA or Low/Int-1 Risk MDS Recruiting
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA) Recruiting 3 months and older
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA) Recruiting 3 months and older
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant Recruiting up to 75 years
Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) (CHAMP) Recruiting up to 75 years
Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome Recruiting 18 years and older

AAMDSIF does not recommend, endorse, or make any representation about the efficacy, appropriateness or suitability of any drug, treatment or therapy listed on this website. Some therapies listed on our site are considered experimental for the treatment of bone marrow failure diseases. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding any therapy, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.